Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
EXACT Sciences Corporation | EXAS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
61.41 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 56.05 - 100.77 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 61.41 | USD |
EXACT Sciences Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
11.15B | 181.53M | - | 2.58B | -204.15M | -1.12 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
EXACT Sciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EXAS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 59.06 | 63.99 | 57.97 | 61.59 | 1,992,661 | 2.35 | 3.98% |
1 Month | 71.82 | 73.81 | 57.5529 | 64.19 | 2,374,793 | -10.41 | -14.49% |
3 Months | 60.28 | 79.62 | 56.05 | 64.32 | 2,534,905 | 1.13 | 1.87% |
6 Months | 64.74 | 79.62 | 56.05 | 65.14 | 2,094,303 | -3.33 | -5.14% |
1 Year | 67.30 | 100.77 | 56.05 | 72.08 | 1,854,636 | -5.89 | -8.75% |
3 Years | 104.40 | 133.99 | 29.27 | 67.87 | 1,941,306 | -42.99 | -41.18% |
5 Years | 103.94 | 159.54 | 29.27 | 80.52 | 1,905,273 | -42.53 | -40.92% |
EXACT Sciences Description
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in multi-cancer liquid biopsy cancer screening. |